The content on this site is intended for healthcare professionals only
Dr Samantha Jaglowski talks to ecancer at the ASCO 2012 Annual Meeting, Chicago, about the early phase ibrutinib trial.
Ibrutinib, an irreversible inhibitor of the Bruton’s tyrosine kinase, treats chronic lymphocytic leukaemia by blocking the activation of B cells, ultimately leading to apoptosis.
Patients were treated in both a refractory and frontline setting with ibrutinib used as a single agent and in combination with ofatumumab. Early results showed response in all patients.
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Relapsed refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment
Venetoclax and ibrutinib therapy shows favourable results in the treatment of R/R chronic lymphocytic leukaemia
Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma
